MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
Big Improvements in Clinical Trial Transparency Compliance
Bioethics International recently published their second, long-promised Good Pharma Scorecard, a ranking of large biopharmaceutical companies’ compliance with disclosing data for new medicines to public registries, in BMJ Open. With this recent publication, a spotlight...
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and...
Complimentary Webinar: Optimizing the Use of Clinical Trial Disclosure Systems
MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.” Learning Objectives Determine key drivers for the use of technology to...
Pfizer Selects MMS as Preferred Provider for Plain Language Summary Writing Support
Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials. In advance of implementation of EU Clinical Trial Regulation No....
Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope
In the United States, the number of patients with Alzheimer’s disease is projected to increase from the current prevalence of around 5.5 million to around 14 million in 2050. These sobering numbers reflect an urgent need for increased awareness and proactive decision...
Emmaus Medical’s New Drug Application for Sickle Cell Disease Recommended for Approval by FDA
Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that...
MMS Gives Back: Flint Water Distribution
In an effort to give back to our community, MMS colleagues worked with the American Red Cross to deliver water to our neighbors in Flint, Michigan. On Wednesday, March 9, the MMS team was able to deliver 190 cases of water and numerous water filters to over 140 homes....
MMS Funds $1 Million Zika Vaccine Development Award
Canton, Mich. (March 14, 2016) — MMS Holdings Inc., a specialty data-focused CRO, has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial...
MMS Announces Expansion of Asia Operations In Hyderabad
HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India. The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality...
6880 Commerce Blvd.
Canton, MI 48187 USA
734.245.0310 T
734.245.0320 F
CONNECT WITH US